Skip to Main Content

Author Details

Robert H Shoemaker
National Cancer Institute
1978
193
50
PMIDPaper TitleJournal TitlePublished Year
36674695Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1.Int J Mol Sci2023
37746286Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer.Front Oncol2023
37880313Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention.NPJ Precis Oncol2023
36715493Genetically engineered mouse models for hereditary cancer syndromes.Cancer Sci2023
37270364Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.Vaccine2023
36875137Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.Front Immunol2023
37384752The ribosome-inactivating proteins MAP30 and Momordin inhibit SARS-CoV-2.PLoS One2023
36674695Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1.Int J Mol Sci2023
37746286Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer.Front Oncol2023
37880313Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention.NPJ Precis Oncol2023
37384752The ribosome-inactivating proteins MAP30 and Momordin inhibit SARS-CoV-2.PLoS One2023
37270364Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.Vaccine2023
36715493Genetically engineered mouse models for hereditary cancer syndromes.Cancer Sci2023
36875137Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.Front Immunol2023
36193659Targeting the Leukotriene Pathway for Colon Cancer Interception.Cancer Prev Res (Phila)2022
35452553Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.Mol Carcinog2022
35816490Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.PLoS One2022
35804881Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.Cancers (Basel)2022
35992328Methylated Septin9 (m<i>SEPT9</i>): A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer.Cancer Res Commun2022
35861366Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.Adv Sci (Weinh)2022
36193659Targeting the Leukotriene Pathway for Colon Cancer Interception.Cancer Prev Res (Phila)2022
35781796Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.EMBO Mol Med2022
35804881Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.Cancers (Basel)2022
35861366Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.Adv Sci (Weinh)2022
35452553Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.Mol Carcinog2022
35816490Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.PLoS One2022
35781796Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.EMBO Mol Med2022
35992328Methylated Septin9 (m<i>SEPT9</i>): A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer.Cancer Res Commun2022
32641470Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.Gut2021
34236760Pulmonary Aerosol Delivery of Let-7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment.Adv Sci (Weinh)2021
33742401Evaluation of Real-Time In Vitro Invasive Phenotypes.Methods Mol Biol2021
33476764Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine.Nanomedicine2021
34224739Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.Gastroenterology2021
33573433Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.Hum Vaccin Immunother2021
34302042Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA.Commun Biol2021
32641470Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.Gut2021
35047458Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.J Cancer Prev2021
34772932WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.Nat Commun2021
34545368Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.bioRxiv2021
34545364Development of a novel, pan-variant aerosol intervention for COVID-19.bioRxiv2021
35008201Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.Cancers (Basel)2021
33742401Evaluation of Real-Time In Vitro Invasive Phenotypes.Methods Mol Biol2021
33573433Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.Hum Vaccin Immunother2021
35008201Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.Cancers (Basel)2021
35047458Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.J Cancer Prev2021
34545368Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.bioRxiv2021
34545364Development of a novel, pan-variant aerosol intervention for COVID-19.bioRxiv2021
34772932WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.Nat Commun2021
34224739Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.Gastroenterology2021
34302042Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA.Commun Biol2021
  • 1 - 50 of 386

Recommended Authors

Jos?? Manuel Calder??n-Monta??o
Faculty of Pharmacy, University of Seville
Career Start Year 2010
Number of shared co-authors 0
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 6
Stephane Ferretti
Novartis Institutes for BioMedical Research
Career Start Year 2003
Number of shared co-authors 1
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 7
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 8
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Rima Al-Awar
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1999
Number of shared co-authors 0
Christopher Calabrese
St. Jude Children's Research Hospital
Career Start Year 1997
Number of shared co-authors 0
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 2
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 0
Rengul Cetin-Atalay
Middle East Technical University
Career Start Year 1994
Number of shared co-authors 1
Barry R Davies
Oncology R&D
Career Start Year 1992
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 1
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 12
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 2
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 0
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 9
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 1
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 1
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 2
David W Hedley
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1975
Number of shared co-authors 0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 1
Waldemar Priebe
The University of Texas MD Anderson Cancer Center
Career Start Year 1972
Number of shared co-authors 1
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 4
John N Weinstein
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 15

Collaborators

Dominic A Scudiero
Co-authored papers 29
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Co-authored papers 17
James B McMahon
Center for Cancer Research, National Cancer Institute
Co-authored papers 7
Yves Pommier
Center for Cancer Research, National Cancer Institute
Co-authored papers 7
Mark Raffeld
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
David S Schrump
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Ligia A Pinto
Frederick National Laboratory for Cancer Research
Co-authored papers 3
Alan Rein
Co-authored papers 3
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Co-authored papers 2
Michael M Lieber
Mayo Clinic College of Medicine
Co-authored papers 2
Eduardo Vilar
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Kunio Nagashima
Co-authored papers 2
Nuria Montserrat
Catalan Institution for Research and Advanced Studies (ICREA)
Co-authored papers 2
Ian Crozier
Christchurch Hospital
Co-authored papers 2
John Connelly
Institute of Genetics and Cancer, University of Edinburgh
Co-authored papers 2
Ogan D Abaan
Illumina Inc.
Co-authored papers 1
Huib Ovaa
Leiden University Medical Center
Co-authored papers 1
Michael Murphy
Co-authored papers 1
James J Hsieh
Washington University
Co-authored papers 1
William C Reinhold
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
Peer Bork
University of Wurzburg
Co-authored papers 1
Natasha J Caplen
Co-authored papers 1
Olivier Elemento
Meyer Cancer Center
Co-authored papers 1
Robert M Stephens
Frederick National Laboratory for Cancer Research, Inc.
Co-authored papers 1
Elena M Stoffel
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 1
Garth Powis
PHusis Therapeutics Inc.
Co-authored papers 1
Powel H Brown
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Levy Kopelovich
Co-authored papers 1
Ivet Bahar
Laufer Center for Physical and Quantitative Biology, Stony Brook University
Co-authored papers 1
Release 1.2